Breast Cancer Research and Treatment

, Volume 92, Issue 2, pp 169–174 | Cite as

Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant

  • J.F.R. RobertsonEmail author
  • A. Howell
  • V.A. Gorbunova
  • T. Watanabe
  • T. Pienkowski
  • M.R. Lichinitser


There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician’s discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy.


advanced breast cancer endocrine sequencing fulvestrant sensitivity to subsequent treatment tamoxifen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group,1998Tamoxifen for early breast cancer: an overview of the randomised trialsLancet35114511467Google Scholar
  2. 2.
    Wakeling, AE, Dukes, M, Bowler, J 1991A potent specific pure antiestrogen with clinical potentialCancer Res5138673873PubMedGoogle Scholar
  3. 3.
    Robertson, JF, Nicholson, RI, Bundred, NJ, Anderson, E, Rayter, Z, Dowsett, M, Fox, JN, Gee, JM, Webster, A, Wakeling, AE, Morris, C, Dixon, M 2001Comparison of the short-term biological␣effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancerCancer Res6167396746PubMedGoogle Scholar
  4. 4.
    Howell, A, Robertson, JFR, Quaresma Albano, J, Aschermannova, A, Mauriac, L, Kleeberg, UR, Vergote, I, Erikstein, B, Webster, A, Morris, C 2002Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatmentJ Clin Oncol2033963403PubMedGoogle Scholar
  5. 5.
    Osborne, CK, Pippen, J, Jones, SE, Parker, LM, Ellis, M, Come, S, Gertler, SZ, May, JT, Burton, G, Dimery, I, Webster, A, Morris, C, Elledge, R, Buzdar, A 2002Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trialJ␣Clin Oncol2033863395PubMedGoogle Scholar
  6. 6.
    Pippen, J, Osborne, CK, Howell, A, Robertson, JFR 2003Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trialsBreast Cancer Res Treat82 S101 (abstract 426)Google Scholar
  7. 7.
    Howell, A, Robertson, JFR, Abram, P, Lichinitser, MR, Elledge, R, Bajetta, E, Watanabe, T, Morris, C, Webster, A, Dimery, I, Osborne, CK 2004Comparison of fulvestrant v tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trialJ Clin Oncol2216051613PubMedGoogle Scholar
  8. 8.
    Buzdar, AU, Jonat, W, Howell, A, Jones, SE, Blomqvist, CP, Vogel, CL, Eiermann, W, Wolter, JM, Steinberg, M, Webster, A, Lee, D 1998Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study GroupCancer8311421152PubMedGoogle Scholar
  9. 9.
    Kvinnsland, S, Anker, G, Dirix, LY, Bonneterre, J, Prove, AM, Wilking, N, Lobelle, JP, Mariani, O, Salle, E, Polli, A, Massimini, G 2000High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatmentEur J Cancer36976982PubMedGoogle Scholar
  10. 10.
    Vergote, I, Robertson, JFR, Kleeberg, U, Burton, G, Osborne, CK, Mauriac, L 2003Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapyBreast Cancer Res Treat79207211PubMedGoogle Scholar
  11. 11.
    Perey, L, Thürlimann, B, Hawle, H, Bonnefoi, H, Ahern, J, Pagani, O, Goldhirsch, A, Dietrich, D 2002Fulvestrant (’Faslodex’) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitorsBreast Cancer Res Treat76 S72(abstract 249)Google Scholar
  12. 12.
    Steger, G, Bartsch, R, Wenzel, C, Pluschnig, U, Hussain, D, Mader, RM, Zielinski, CC 2003Fulvestrant (Faslodex®) in metastatic breast cancerBreast Cancer Res Treat82 S104(abstract 437)Google Scholar
  13. 13.
    Franco, S, Perez, A, Tan-Chiu, E, Frankel, C, Vogel, CL 2003Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer: a single-center experienceBreast Cancer Res Treat82 S105(abstract 429)Google Scholar
  14. 14.
    Petruzelka L, Zimovjanova M: Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – results from an expanded access programme. Eur J Cancer (Suppl 2): 132, 2004 (abstract 264)Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • J.F.R. Robertson
    • 1
    Email author
  • A. Howell
    • 2
  • V.A. Gorbunova
    • 3
  • T. Watanabe
    • 4
  • T. Pienkowski
    • 5
  • M.R. Lichinitser
    • 3
  1. 1.Unit of SurgeryCity HospitalNottinghamUK
  2. 2.Christie HospitalManchesterUK
  3. 3.Cancer Research Center of Russian Academy of Medical SciencesMoscowRussia
  4. 4.International University of Health and WelfareTochigiJapan
  5. 5.Centrum Onkologiiim M Sklodowskiej-CurieWarsawPoland

Personalised recommendations